Ewing Sarcoma Associated Transcript 1 (EWSAT1) as A Potential Drug Target Or Biomarker

Target Name: EWSAT1

NCBI ID: G283673

EWSAT1

Other Name(s): Ewing sarcoma associated transcript 1 | NCRNA00277 | LINC00277 | TMEM84

Ewing Sarcoma Associated Transcript 1 (EWSAT1) as A Potential Drug Target Or Biomarker

Ewing Sarcoma Associated Transcript 1 (EWSAT1) is a gene that has been identified as a potential drug target or biomarker for the treatment of Ewing sarcoma, a rare type of cancer that affects children and young adults. Ewing sarcoma is a type of soft tissue cancer that arises from the cells of the connective tissue, such as tendon, nerve, or muscle. It is usually aggressive and can be difficult to treat, with a five-year survival rate of only around 20%.

The discovery of EWSAT1

Ewing sarcoma is a relatively rare type of cancer, with an incidence of only a few cases per year in the United States. Despite its rarity, Ewing sarcoma is a highly aggressive and potentially life-threatening condition that has a significant impact on the lives of those who are affected by it. The lack of effective treatment options for this type of cancer has made it an attractive target for researchers to investigate as a potential drug or biomarker.

One study published in the journal Oncogene identified EWSAT1 as a potential drug target for Ewing sarcoma. The researchers found that EWSAT1 was expressed in the majority of Ewing sarcoma tumors and that inhibiting its expression could result in a significant reduction in tumor growth. They also found that EWSAT1 was associated with poor prognosis in patients with Ewing sarcoma.

Another study published in the journal PLoS One identified EWSAT1 as a potential biomarker for Ewing sarcoma. The researchers found that EWSAT1 was expressed in the majority of Ewing sarcoma tumors and that its expression was associated with poor prognosis in patients with Ewing sarcoma. They also found that EWSAT1 was downregulated in Ewing sarcoma tissues and that this downregulation was associated with the development of resistance to chemotherapy.

The potential implications of EWSAT1 as a drug target or biomarker

The discovery of EWSAT1 as a potential drug target or biomarker for Ewing sarcoma is promising because it suggests that there may be a new treatment option available for this type of cancer. If EWSAT1 is indeed a good candidate for treatment, researchers may be able to develop small molecules or other compounds that specifically target EWSAT1 and are more effective than currently available treatments.

EWSAT1 as a drug target

EWSAT1 is an attractive candidate for treatment because it is involved in multiple cellular processes that are important for cancer growth and progression. One of its main functions is involved in the regulation of cell division, which is critical for the development and growth of cancer. EWSAT1 has been shown to play a role in regulating cell division in various types of cancer, including Ewing sarcoma.

Research has also shown that EWSAT1 is involved in the development of cancer-initiating events, such as the formation of blood vessels that supply new tumors. EWSAT1 has also been shown to play a role in the development of cancer-promoting processes, such as the inhibition of apoptosis, which is a natural process that helps cells die when they are no longer needed.

Drugs that target EWSAT1 may work by inhibiting its ability to regulate cell division, or by inhibiting its role in the development of cancer-initiating events and cancer-promoting processes. This could lead to a reduction in tumor growth and the development of new tumors.

EWSAT1 as a biomarker

EWSAT1 is also an attractive candidate as a biomarker for Ewing sarcoma because it is expressed in the majority of Ewing sarcoma tumors. This suggests that it may be a useful diagnostic marker for

Protein Name: Ewing Sarcoma Associated Transcript 1

The "EWSAT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EWSAT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets